Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 86
- Registration Number
- NCT05849922
- Locations
- 🇺🇸
Center for Clinical Studies, LTD. LLP Site Number : 8400003, Houston, Texas, United States
🇦🇺Investigational Site Number : 0360002, Liverpool, New South Wales, Australia
🇫🇷Investigational Site Number : 2500004, Saint Mande, France
A First-in-human Single and Repeated Dose Escalation Study of SAR442501 in Healthy Adults Subjects
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 76
- Registration Number
- NCT05846009
- Locations
- 🇺🇸
Investigational site, Newark, New Jersey, United States
A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 60
- Registration Number
- NCT05844735
- Locations
- 🇺🇸
TKL Research, Inc. Site Number : 8400001, Fair Lawn, New Jersey, United States
Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult Subjects
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 56
- Registration Number
- NCT05845996
- Locations
- 🇺🇸
PPD-Site Number:8400001, Austin, Texas, United States
A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
- Conditions
- Relapsed/Refractory Multiple MyelomaAmyloid Light-chain Amyloidosis
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 32
- Registration Number
- NCT05839626
- Locations
- 🇬🇧
Investigational Site Number : 8260002, London, United Kingdom
🇬🇧Investigational Site Number : 8260001, Manchester, United Kingdom
🇦🇺Investigational Site Number : 0360001, Wollongong, New South Wales, Australia
Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 Months
- Conditions
- Influenza
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 682
- Registration Number
- NCT05832333
- Locations
- 🇰🇷
Site 006, Gyeongsangnam-do, Korea, Republic of
🇰🇷Site 010, Gyeongsangnam-do, Korea, Republic of
🇰🇷Site 002, Gwangju, Korea, Republic of
A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness
- Conditions
- Venous Thromboembolism
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 14799
- Registration Number
- NCT05819112
- Locations
- 🇺🇸
Sanofi U.S., Bridgewater, New Jersey, United States
Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin
- Conditions
- Venous Thromboembolism
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 21000
- Registration Number
- NCT05819125
- Locations
- 🇺🇸
Sanofi U.S., Bridgewater, New Jersey, United States
A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)
- Conditions
- Amyotrophic Lateral Sclerosis (Healthy Volunteers)
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT05797701
- Locations
- 🇺🇸
Prism Research-Site Number:8400001, Saint Paul, Minnesota, United States
A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)
- Conditions
- Amyotrophic Lateral SclerosisHealthy Volunteer
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT05797753
- Locations
- 🇺🇸
Nucleus Network Site Number : 8400001, Saint Paul, Minnesota, United States